On December 16, Gelonghui reported that Chuan Ning Biological (301301.SZ) stated on the investor interaction platform that the company's research and development expenses in the first three quarters of 2024 amounted to 44.0661 million yuan, an increase of 12.82% year-on-year, with a continuous growth in R&D expenses. The main reason for the relatively low proportion of total revenue is that the company's revenue is growing rapidly; the company's R&D investment is mainly in the synthetic biology Sector, which has a relatively high overall R&D input-output ratio.
Clear
All
Quotes
News
Learn
Help
All
HK
US
CN
SG
AU
JP
All
News
Announcements
Reports
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh
Refresh
Loading
History record
Latest News
Quotes
More
News
More
Learn
More
Help
More
Loading
News
More
Announcements
More
Reports
More
川宁生物(301301.SZ):研发投入主要在合成生物学板块
Crown Bio (301301.SZ): Research and development investment mainly in the synthetic biology Sector.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Like
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Comment(0)
Reason For Report